Eli Lilly gets on the trial transparency bandwagon

In keeping changing with industry standards, Eli Lilly ($LLY) has joined the host of drugmakers opening up their data vaults, going further than some but not quite baring it all. Lilly has signed up with ClinicalStudyDataRequest.com to share anonymized results with researchers approved by an independent panel. The pharma giant will disclose mid- to late-stage data from studies used for regulator approvals on or after 1999; trials launched after Jan. 1, 2007; and regional or local studies for indications approved in 2014 or later. Lilly's efforts go beyond those of Sanofi ($SNY) and Bayer, which will share only data on newly approved products, but fall shore of the efforts of GlaxoSmithKline ($GSK) and Johnson & Johnson ($JNJ). More